(AOF) – Solvay has signed a partnership agreement with Shanghai Shengjian Environment Technology Co. in order to strengthen their commercial relations and develop together in new markets. Under the new agreement, Solvay and Shengjian will jointly promote the development and commercialization of components, systems and processes in the semiconductor, flat panel display, solar energy sectors and develop other demanding industries through to deeper cooperation.
“Shengjian occupies a leading position in flat panel display and semiconductor applications, supported by our sourcing of innovative materials, and seeks to drive business growth through our technical support and high-quality product portfolio. performance,” says Peter Browning, President of Solvay’s Specialty Polymers Global Business Unit. “By strengthening the close ties between our companies, this agreement will also create a win-win situation to capture new business opportunities and strengthen our ties with strategic end customers.”
AOF – LEARN MORE
Learn more about the chemicals sector
Nothing is going well for German chemistry
German chemicals, very dependent on Russian gas, are in difficulty. Following sluggish sales in the automotive sector and falling demand in construction, production is down 8.5% in 2022, with overall turnover down 1.6% to 63.1 Billions of Euro’s. Specialty chemistry is doing better. On the other hand, the rate of utilization of production capacities in basic chemicals has slowed significantly to reach less than 80%. The third German industrial sector is tempted by relocation to the United States, where energy costs are much lower. With the Inflation Reduction Act, the United States has established an environment appropriate to current challenges.
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.